Q4 2017 Earnings Estimate for Sarepta Therapeutics, Inc. (SRPT) Issued By SunTrust Banks

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at SunTrust Banks upped their Q4 2017 EPS estimates for Sarepta Therapeutics in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash now expects that the biotechnology company will earn ($0.28) per share for the quarter, up from their prior forecast of ($0.73). SunTrust Banks currently has a “Buy” rating and a $56.00 target price on the stock. SunTrust Banks also issued estimates for Sarepta Therapeutics’ Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.08) EPS, FY2018 earnings at ($0.29) EPS and FY2019 earnings at ($0.06) EPS.

Other research analysts have also issued research reports about the stock. Credit Suisse Group reiterated an “outperform” rating and set a $81.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Robert W. Baird reiterated a “buy” rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. Leerink Swann reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, July 3rd. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Finally, Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus price target of $64.10.

ILLEGAL ACTIVITY WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/30/q4-2017-earnings-estimate-for-sarepta-therapeutics-inc-srpt-issued-by-suntrust-banks.html.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 47.79 on Monday. The company’s market cap is $3.07 billion. The firm’s 50 day moving average is $48.16 and its 200-day moving average is $38.57. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $52.67.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 62.44%. The business had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. During the same quarter last year, the firm earned ($0.95) earnings per share.

In other news, SVP Shamim Ruff sold 11,500 shares of the stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in SRPT. Prentiss Smith & Co. Inc. increased its position in Sarepta Therapeutics by 772.2% during the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Sarepta Therapeutics by 150.1% during the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in Sarepta Therapeutics by 116.4% during the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the last quarter. Finally, Edge Wealth Management LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth about $175,000. Hedge funds and other institutional investors own 65.46% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

What are top analysts saying about Sarepta Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit